Linagliptin/Metformin Hydrochloride Rowex

Linagliptin/Metformin Hydrochloride, the active ingredient in Linagliptin/Metformin Hydrochloride Rowex, is a DPP‑4 inhibitor; biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, used as part of a comprehensive glycemic control plan.

GNH USA supplies Linagliptin/Metformin Hydrochloride Rowex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards.

Linagliptin/Metformin Hydrochloride is used within the antidiabetic drug class to improve glycaemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus (initial therapy): reduces fasting and post‑prandial glucose levels when combined with diet and exercise. - Type 2 diabetes mellitus (add‑on therapy): provides additional HbA1c reduction when metformin alone does not achieve target levels. - Type 2 diabetes mellitus (combination therapy): supports overall glycaemic management as part of a multi‑drug regimen alongside other antidiabetic agents.

Adverse reactions may occur with Linagliptin/Metformin Hydrochloride and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute pancreatitis: sudden abdominal pain with elevated enzymes. - Renal impairment: worsening kidney function. - Allergic reactions: rash, angioedema, or anaphylaxis. - Hepatotoxicity: abnormal liver function tests.

When prescribing Linagliptin/Metformin Hydrochloride, clinicians should consider several safety aspects.

- Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal impairment or hepatic disease. - Hypoglycaemia monitoring: increase vigilance when used with insulin or sulfonylureas. - Pregnancy and lactation: prescribe only if potential benefits outweigh risks. - Drug‑interaction review: assess concomitant medications for possible interactions. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Linagliptin/Metformin Hydrochloride may interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: heightened risk of hypoglycaemia. - Iodinated contrast agents: may precipitate renal dysfunction with metformin. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase linagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Beta‑blockers: can mask symptoms of hypoglycaemia.